Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs
- PMID: 10986302
- DOI: 10.1093/rheumatology/39.9.975
Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs
Abstract
Objective: To summarize the evidence on treatment withdrawal rates reported in observational studies and randomized controlled trials (RCTs) of methotrexate (MTX), parenteral gold (GST), sulphasalazine (SSZ) and hydroxychloroquine (HCQ) among patients with rheumatoid arthritis (RA).
Methods: Two independent Medline searches were used to retrieve relevant studies published between 1966 and 1997. Those which disclosed information on the number of patients withdrawing from the drug were retained. Cumulative probabilities of survival on treatment were then computed using actuarial survival estimates, and differences were tested using log-rank, Wilcoxon and Cox proportional hazards tests.
Results: A total of 159 studies provided withdrawal information, and the numbers of patients who withdrew, in general or because of inefficacy or toxicity, could be abstracted from 110 studies contributing 142 treatment arms (MTX, 48; GST, 56; SSZ, 22; HCQ, 16). Data for HCQ were available only up to 24 months, but combined percentages of patients estimated to have continued MTX, GST or SSZ, respectively, for 60 months were 36, 23 and 22% when all failures were considered, 75, 73 and 53% when withdrawals due to lack of efficacy alone were considered, and 65, 36 and 48% when only withdrawals due to toxicity were taken into account. The Cox proportional hazards test performed on all withdrawals, after adjusting for year of publication and type of study, revealed that patients remained on MTX significantly longer than they did on the other three agents; however, the patients stayed significantly longer on GST than MTX when withdrawals for inefficacy were analysed separately. No significant differences in withdrawal rates were noted between observational studies and RCTs.
Conclusion: Patients with RA stay significantly longer on MTX than on other disease-modifying anti-rheumatic drugs. Higher withdrawal rates among those given GST are mainly due to high toxicity, whereas the majority of withdrawals from SSZ and HCQ result from lack of efficacy. Withdrawal rates in observational studies are similar to those reported in RCTs.
Similar articles
-
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.Ann Rheum Dis. 2013 Dec;72(12):1927-33. doi: 10.1136/annrheumdis-2012-202062. Epub 2012 Nov 29. Ann Rheum Dis. 2013. PMID: 23196701 Clinical Trial.
-
Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.Arthritis Care Res (Hoboken). 2021 Aug;73(8):1114-1124. doi: 10.1002/acr.24253. Arthritis Care Res (Hoboken). 2021. PMID: 32374918
-
Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials.J Rheumatol. 1999 Oct;26(10):2123-30. J Rheumatol. 1999. PMID: 10529127
-
A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.Rheumatology (Oxford). 2005 Nov;44(11):1414-21. doi: 10.1093/rheumatology/kei031. Epub 2005 Jul 19. Rheumatology (Oxford). 2005. PMID: 16030080 Review.
-
Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.Semin Arthritis Rheum. 2014 Apr;43(5):613-26. doi: 10.1016/j.semarthrit.2013.09.005. Epub 2013 Oct 5. Semin Arthritis Rheum. 2014. PMID: 24231065 Review.
Cited by
-
Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.Chest. 2012 Nov;142(5):e1S-e111S. doi: 10.1378/chest.12-1044. Chest. 2012. PMID: 23131960 Free PMC article.
-
Risk of Liver Fibrosis in Methotrexate-Treated Patients: A Systematic Review.Cureus. 2022 Oct 31;14(10):e30910. doi: 10.7759/cureus.30910. eCollection 2022 Oct. Cureus. 2022. PMID: 36465792 Free PMC article. Review.
-
Sulfasalazine: a review of its use in the management of rheumatoid arthritis.Drugs. 2005;65(13):1825-49. doi: 10.2165/00003495-200565130-00008. Drugs. 2005. PMID: 16114981 Review.
-
Comparing the long-term clinical outcome of treatment with methotrexate or sulfasalazine prescribed as the first disease-modifying antirheumatic drug in patients with inflammatory polyarthritis.Ann Rheum Dis. 2006 Nov;65(11):1449-55. doi: 10.1136/ard.2005.049775. Epub 2006 Mar 15. Ann Rheum Dis. 2006. PMID: 16540547 Free PMC article. Clinical Trial.
-
Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs.Ann Rheum Dis. 2004 Feb;63(2):131-7. doi: 10.1136/ard.2003.006494. Ann Rheum Dis. 2004. PMID: 14722200 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials